US FTC approves Aurobindo Pharma acquisition of Lannett business

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹1447.30

prior close

₹1454.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.3%+3.3% vs market

Pharmaceuticals peers, median of 160sector+0.4%+3.2% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Midcap 150 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.9

15m

+0.3

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+0.3+3.3+0.4+3.2

Next day

+3.4+0.8+2.6+0.5+2.8

+6.0-0.2+6.2+1.7+4.4

+5.8-0.1+5.9+1.7+4.1

+7.4-0.6+8.0+0.9+6.5

+6.3-0.9+7.2+1.5+4.8

+7.1-0.3+7.4+2.7+4.4

15d

+7.0+1.2+5.8+4.1+2.9

+7.7+0.8+6.8+4.0+3.7

+12.2+1.8+10.4+2.0+10.2

+18.7-0.3+19.0+7.7+11.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma has received the necessary approvals from the US Federal Trade Commission (FTC) for its acquisition of Lannett business. This is a key regulatory clearance that brings the deal closer to completion. Lannett is a US-based generic pharmaceutical company. The intimation confirms that the antitrust review by the FTC has been satisfied, clearing a major hurdle for the transaction.

Likely market impact

Removes a key regulatory hurdle, moving the Lannett acquisition closer to closing and supporting Aurobindo's US generics expansion.